当前位置: X-MOL 学术Expert Opin. Drug Deliv. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Nucleic acid-loaded lipid-polymer nanohybrids as novel nanotherapeutics in anticancer therapy.
Expert Opinion on Drug Delivery ( IF 5.0 ) Pub Date : 2020-05-06 , DOI: 10.1080/17425247.2020.1757645
Mahfoozur Rahman 1 , Khalid S Alharbi 2 , Nabil K Alruwaili 3 , Nisrin Anfinan 4 , Waleed H Almalki 5 , Ipsa Padhy 6 , Unnam Sambamoorthy 7 , Suryakanta Swain 8 , Sarwar Beg 9
Affiliation  

Introduction: Since decades, cancer is a major public health problem worldwide. The increasing knowledge of molecular and tumor biology has significantly changed the cancer treatment paradigms during the past few years.Area covered: Conventionally, the first-line treatment of solid tumors is their surgical removal followed by chemotherapy and/or radiation treatment. Unfortunately, these approaches often fail, and the patient may discontinue the treatment before the complete eradication of tumors due to therapeutic and toxicological limitations. In this regard, the nucleic acid-based treatment therapy has been widely used in the management of cancer. However, nucleic acid delivery to the target sites is highly challenging because of their molecular size, difficulties to pass cellular membranes, and susceptibility toward enzymatic and/or chemical degradation.Expert opinion: Researchers have now overcome many problems associated with delivering nucleic acids to the target tissues by preventing them from off-target side effects and overcoming rapid degradation and clearance in the bloodstream using the lipid-polymer hybrid nanoparticles (LPHNs). The present review, therefore, aims to provide an overview account on LPNHs, their preparation, characterization, application with special emphasis on intracellular delivery/transfection of nucleic acids in the management of cancer, and key aspects of challenges in its delivery and clinical transition.

中文翻译:

载有核酸的脂质聚合物纳米杂化物作为抗癌治疗中的新型纳米疗法。

简介:几十年来,癌症一直是全球范围内的主要公共卫生问题。在过去的几年中,越来越多的分子和肿瘤生物学知识大大改变了癌症治疗的范式。涵盖的领域:传统上,实体瘤的一线治疗是手术切除,然后进行化学疗法和/或放射治疗。不幸的是,这些方法经常失败,并且由于治疗和毒理学限制,患者可能在彻底根除肿瘤之前中断治疗。在这方面,基于核酸的治疗疗法已广泛用于癌症的治疗中。但是,由于核酸分子大小,难以通过细胞膜,专家意见:研究人员现已克服了许多与核酸输送至目标组织有关的问题,方法是防止核酸脱离靶标副作用,并使用脂质-脂质体克服血液中的快速降解和清除。聚合物杂化纳米颗粒(LPHN)。因此,本综述旨在提供有关LPNHs,其制备,表征,在癌症治疗中特别侧重于核酸的细胞内递送/转染的应用以及其递送和临床转化挑战的关键方面的概述。现在,研究人员通过使用脂质-聚合物杂化纳米颗粒(LPHN)防止核酸脱离靶标副作用并克服血液中的快速降解和清除作用,从而克服了将核酸递送至靶标组织的许多问题。因此,本综述旨在提供有关LPNHs,其制备,表征,在癌症治疗中特别侧重于核酸的细胞内递送/转染的应用以及其递送和临床转化挑战的关键方面的概述。现在,研究人员通过使用脂质-聚合物杂化纳米颗粒(LPHN)防止核酸脱离靶标副作用并克服血液中的快速降解和清除作用,从而克服了将核酸递送至靶标组织的许多问题。因此,本综述旨在提供有关LPNHs,其制备,表征,在癌症治疗中特别侧重于核酸的细胞内递送/转染的应用以及其递送和临床转化挑战的关键方面的概述。
更新日期:2020-05-06
down
wechat
bug